According to the Zhitong Finance App, Mailand (688273.SH) released its 2022 annual performance report. During the reporting period, the company's total revenue was 377 million yuan, up 10.28% year on year; operating profit was 149 million yuan, up 14.44% year on year; total profit was 149 million yuan, up 14.71% year on year; net profit attributable to parent company owners was 123 million yuan, up 3.93% year on year. Net profit attributable to parent company owners after deducting non-recurring profit and loss was 89.259 million yuan, down 14.70% year on year.

The main reason for the increase in the company's performance during the reporting period was that the company continued to be innovation-driven and invested in new product research and development, and launched a series of new pelvic floor diagnosis and treatment products and new female reproductive rehabilitation equipment this year, which provided new impetus for performance growth; second, during the reporting period, the company's non-recurring profit and loss increased compared to the previous year, mainly: a. Idle fund management revenue increased; b. The company undertook national key R&D projects and provincial key core technology (equipment) research projects received government funding support.